SCHEMBL3566091

SCHEMBL3566091

O=C(Nc1ccc(Cl)cc1)NC(C(=O)Nc1ccc(-c2cccc[n+]2[O-])cc1)c1ccccc1Oc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 2/20 0.41
PCTP Q9UKL6 1/20 0.39
P2RY1 P47900 1/20 0.39
MAPK1 P28482 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DGAT1 O75907 2/20 0.37
CSGALNACT1 Q8TDX6 1/20 0.37
XIAP P98170 1/20 0.37
CNR1 P21554 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560707 0.90 PCTP (0.48) UTS2RPCTPMAPK1MEN1KMT2A
SCHEMBL3561430 0.87 PCTP (0.38) UTS2RPCTPP2RY1MEN1KMT2A
SCHEMBL3560100 0.86 PCTP (0.45) UTS2RPCTPMEN1KMT2ANPC1
SCHEMBL3559165 0.84 CNR1 (0.38) UTS2RPCTPMEN1KMT2ACNR1
SCHEMBL3562246 0.84 CNR1 (0.40) UTS2RPCTPMEN1KMT2AALDH1A1
SCHEMBL3557410 0.84 UTS2R (0.38) UTS2RPCTPMEN1KMT2AALDH1A1
SCHEMBL3568269 0.84 CNR1 (0.38) UTS2RPCTPMEN1KMT2AALDH1A1
SCHEMBL3576235 0.82 MEN1 (0.48) UTS2RPCTPMEN1KMT2AALDH1A1
SCHEMBL3566089 0.80 PCTP (0.36) UTS2RPCTPP2RY1MEN1KMT2A
SCHEMBL3560468 0.80 LMNA (0.37) UTS2RPCTPMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 UTS2R 52/4885PCTP 1942/4885P2RY1 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.